<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616716</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-I-104</org_study_id>
    <nct_id>NCT04616716</nct_id>
  </id_info>
  <brief_title>A Food Effect Study of FMTN on Healthy Chinese Adult Subjects</brief_title>
  <official_title>A Randomized,Open,Single-center,Three-cycle,Six-sequence Crossover Study to Investigate the Effects of a High-fat and Low-fat Diet on the Pharmacokinetics of Healthy Chinese Adult Subjects After Oral Administration of FMTN Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess the effect of high-fat and low-fat meal on&#xD;
      the pharmacokinetics of FMTN in Chinese adult healthy subjects.&#xD;
&#xD;
      The secondary objective of the study was to assess the safety of FMTN administered in adult&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Actual">October 20, 2020</completion_date>
  <primary_completion_date type="Actual">September 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1:0-192 hours (h) ;Day10:0-192 h; Day 19:0-19h</time_frame>
    <description>Maximum Observed Plasma Concentration for FMTN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 1:0-192 hours (h);Day 10:0-192 h; Day 19:0-192 h</time_frame>
    <description>Area under the concentration-time curve form 0(pre-dose) to time of last concentration of FMTN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Day 1:0-192 hours (h);Day 10:0-192 h; Day 19:0-19 h</time_frame>
    <description>Area under the concentration-time curve form 0(pre-dose) to infinite time of FMTN</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Health, Subjective</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN fasted in P1,low-fat diet in P2,high-fat diet in P3&#xD;
FMTN administration in fasted condition in period 1,FMTN administration after low-fat diet in period 2,FMTN administration after high-fat diet in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN high-fat diet in P1,fasted in P2,low-fat diet in P3&#xD;
FMTN administration after high-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after low-fat diet in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN low-fat diet in P1,high-fat diet P2,fasted in P3&#xD;
FMTN administration after low-fat diet in period 1,FMTN administration after high-fat diet in period 2,FMTN administration in fasted condition in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN fasted in P1,high-fat diet P2,low-fat diet in P3&#xD;
FMTN administration in fasted condition in period 1,FMTN administration after high-fat diet in period 2,FMTN administration after low-fat diet in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN low-fat diet in P1,fasted P2,high-fat diet in P3&#xD;
FMTN administration after low-fat diet in period 1,FMTN administration in fasted condition in period 2,FMTN administration after high-fat diet in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:FMTN high-fat diet in P1,low-fat diet P2,fasted in P3&#xD;
FMTN administration after high-fat diet in period 1,FMTN administration after low-fat diet in period 2,FMTN administration in fasted condition in period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMTN</intervention_name>
    <description>Single dose of FMTN after high-fat meal,low-fat meal and fast</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign informed consent prior to the test, and fully understand the content, process and&#xD;
             possible adverse reactions of the test;&#xD;
&#xD;
          2. Be able to complete the study according to the requirements of the test plan;&#xD;
&#xD;
          3. Healthy male and female subjects aged 18 to 45 years old (including values at both&#xD;
             ends) on the day of signing the informed consent, with a ratio of 1:1.&#xD;
&#xD;
          4. Subjects have no family planning and take effective contraceptive measures voluntarily&#xD;
             from 2 weeks before screening to 6 months after the last medication. Serum HCG test of&#xD;
             fertile women must be negative before screening;&#xD;
&#xD;
          5. The body weight of male subjects is not less than 50kg, and that of female subjects is&#xD;
             not less than 45kg, and the body mass index (BMI) is within the range of 19-28 kg/m2&#xD;
             (including the critical value);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Abnormalities judged by clinicians as clinically significant, including physical&#xD;
             examination, vital signs examination, electrocardiogram or clinical laboratory&#xD;
             examination, or a history of serious cardiac, liver, kidney, digestive tract, nervous&#xD;
             system, respiratory system, mental and metabolic abnormalities;&#xD;
&#xD;
          2. Those who participated in blood donation with blood donation volume â‰¥400mL within 3&#xD;
             months before taking the first study drug, or those who received blood transfusion;&#xD;
&#xD;
          3. Allergic constitution, including a history of severe drug allergy or drug allergy,&#xD;
             allergy to malate famitinib capsule or its excipients;&#xD;
&#xD;
          4. A history of drug use, drug screening positive or a history of drug abuse in the past&#xD;
             five years or drug use in the 3 months prior to the trial;&#xD;
&#xD;
          5. A history of heavy drinking (14 units of alcohol per week: 1 unit = 285mL beer, 25mL&#xD;
             spirits or 100mL wine);&#xD;
&#xD;
          6. Those who smoked more than 5 cigarettes per day in the first 3 months of the study;&#xD;
&#xD;
          7. women &gt; 470 msec or men &gt;450 msec of QT interval (QTcF) corrected by Fridericia method&#xD;
             in 12-lead electrocardiogram;&#xD;
&#xD;
          8. Left ventricular ejection fraction (LVEF) &lt;50% in cardiac color ultrasound;&#xD;
&#xD;
          9. Screening those who have received any surgery in the previous 6 months;&#xD;
&#xD;
         10. Screening for long-term use of hepatotoxic drugs (such as dapsone, erythromycin,&#xD;
             fluconazole, ketoconazole, rifampicol) within the first 6 months;&#xD;
&#xD;
         11. have taken any clinical trial drug within 3 months prior to the first use of the study&#xD;
             drug;&#xD;
&#xD;
         12. Any drug that alters liver enzyme activity within 4 weeks prior to the first&#xD;
             administration of the study drug;&#xD;
&#xD;
         13. Any prescription or non-prescription drug, any vitamin product, health care product or&#xD;
             herb taken within 2 weeks prior to the first use of the study drug;&#xD;
&#xD;
         14. HCV antibody positive, HIV antibody positive, HBsAg positive, syphilis antibody&#xD;
             positive;&#xD;
&#xD;
         15. Ingestion of grapefruit or products containing grapefruit, caffeine and xanthine foods&#xD;
             or beverages within 48 hours prior to taking the study drug;Strenuous exercise, or&#xD;
             other factors affecting drug absorption, distribution, metabolism, and excretion;&#xD;
&#xD;
         16. have taken any alcoholic product within 24 hours prior to taking the study drug, or&#xD;
             have been screened for alcohol positivity;&#xD;
&#xD;
         17. Subjects who, in the opinion of the investigator, have other factors that are not&#xD;
             appropriate to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

